S&P 500   4,005.45 (+0.64%)
DOW   31,752.19 (+0.54%)
QQQ   300.79 (+0.61%)
AAPL   155.72 (-0.15%)
MSFT   259.56 (+0.57%)
META   161.51 (+0.70%)
GOOGL   109.33 (-0.11%)
AMZN   129.81 (+0.25%)
TSLA   287.70 (+1.41%)
NVDA   138.73 (+1.16%)
NIO   17.58 (+0.57%)
BABA   90.09 (-0.56%)
AMD   82.47 (+3.59%)
T   16.86 (-0.06%)
MU   55.12 (+0.22%)
CGC   3.42 (+0.29%)
F   15.23 (-1.30%)
GE   73.69 (+0.15%)
DIS   112.78 (+0.08%)
AMC   8.57 (+2.15%)
PYPL   96.02 (+1.11%)
PFE   46.71 (+1.26%)
NFLX   227.65 (-0.57%)
S&P 500   4,005.45 (+0.64%)
DOW   31,752.19 (+0.54%)
QQQ   300.79 (+0.61%)
AAPL   155.72 (-0.15%)
MSFT   259.56 (+0.57%)
META   161.51 (+0.70%)
GOOGL   109.33 (-0.11%)
AMZN   129.81 (+0.25%)
TSLA   287.70 (+1.41%)
NVDA   138.73 (+1.16%)
NIO   17.58 (+0.57%)
BABA   90.09 (-0.56%)
AMD   82.47 (+3.59%)
T   16.86 (-0.06%)
MU   55.12 (+0.22%)
CGC   3.42 (+0.29%)
F   15.23 (-1.30%)
GE   73.69 (+0.15%)
DIS   112.78 (+0.08%)
AMC   8.57 (+2.15%)
PYPL   96.02 (+1.11%)
PFE   46.71 (+1.26%)
NFLX   227.65 (-0.57%)
S&P 500   4,005.45 (+0.64%)
DOW   31,752.19 (+0.54%)
QQQ   300.79 (+0.61%)
AAPL   155.72 (-0.15%)
MSFT   259.56 (+0.57%)
META   161.51 (+0.70%)
GOOGL   109.33 (-0.11%)
AMZN   129.81 (+0.25%)
TSLA   287.70 (+1.41%)
NVDA   138.73 (+1.16%)
NIO   17.58 (+0.57%)
BABA   90.09 (-0.56%)
AMD   82.47 (+3.59%)
T   16.86 (-0.06%)
MU   55.12 (+0.22%)
CGC   3.42 (+0.29%)
F   15.23 (-1.30%)
GE   73.69 (+0.15%)
DIS   112.78 (+0.08%)
AMC   8.57 (+2.15%)
PYPL   96.02 (+1.11%)
PFE   46.71 (+1.26%)
NFLX   227.65 (-0.57%)
S&P 500   4,005.45 (+0.64%)
DOW   31,752.19 (+0.54%)
QQQ   300.79 (+0.61%)
AAPL   155.72 (-0.15%)
MSFT   259.56 (+0.57%)
META   161.51 (+0.70%)
GOOGL   109.33 (-0.11%)
AMZN   129.81 (+0.25%)
TSLA   287.70 (+1.41%)
NVDA   138.73 (+1.16%)
NIO   17.58 (+0.57%)
BABA   90.09 (-0.56%)
AMD   82.47 (+3.59%)
T   16.86 (-0.06%)
MU   55.12 (+0.22%)
CGC   3.42 (+0.29%)
F   15.23 (-1.30%)
GE   73.69 (+0.15%)
DIS   112.78 (+0.08%)
AMC   8.57 (+2.15%)
PYPL   96.02 (+1.11%)
PFE   46.71 (+1.26%)
NFLX   227.65 (-0.57%)
NASDAQ:VTRS

Viatris - VTRS Stock Forecast, Price & News

$9.65
-0.07 (-0.72%)
(As of 09/8/2022 10:57 AM ET)
Add
Compare
Today's Range
$9.56
$9.71
50-Day Range
$9.41
$11.13
52-Week Range
$9.32
$15.60
Volume
128,351 shs
Average Volume
9.42 million shs
Market Capitalization
$11.70 billion
P/E Ratio
15.32
Dividend Yield
5.10%
Price Target
$12.40

Viatris MarketRank™ Forecast

Analyst Rating
Hold
1.60 Rating Score
Upside/​Downside
28.4% Upside
$12.40 Price Target
Short Interest
Healthy
1.96% of Shares Sold Short
Dividend Strength
Moderate
Based on Four Factors
Sustainability
N/A
News Sentiment
0.48mentions of Viatris in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$99,875 Sold Last Quarter
Proj. Earnings Growth
-3.24%
From $3.39 to $3.28 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.89 out of 5 stars

Medical Sector

40th out of 1,091 stocks

Pharmaceutical Preparations Industry

13th out of 538 stocks

VTRS stock logo

About Viatris (NASDAQ:VTRS) Stock

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as offers biosimilars franchises, including Fulphila, Ogivri, Hulio, and SEMGLEE. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

Receive VTRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Viatris and its competitors with MarketBeat's FREE daily newsletter.

VTRS Stock News Headlines

September 2022 Stock Considerations - Seeking Alpha
Viatris: Q2 Earnings Snapshot - Greenwich Time
Viatris (VTRS) Surpasses Q2 Earnings Estimates
Dollar's strength impacts revenue at Viatris
Viatris Reports Strong Second Quarter 2022 Results
See More Headlines
Receive VTRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Viatris and its competitors with MarketBeat's FREE daily newsletter.

VTRS Company Calendar

Ex-Dividend for 6/16 Dividend
5/23/2022
Dividend Payable
6/16/2022
Last Earnings
8/08/2022
Ex-Dividend for 9/16 Dividend
8/23/2022
Today
9/08/2022
Dividend Payable
9/16/2022
Next Earnings (Estimated)
11/14/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VTRS
Employees
37,000
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$12.40
High Stock Price Forecast
$19.00
Low Stock Price Forecast
$9.00
Forecasted Upside/Downside
+28.5%
Consensus Rating
Hold
Rating Score (0-4)
1.60
Research Coverage
5 Analysts

Profitability

Net Income
$-1,269,100,000.00
Pretax Margin
5.31%

Debt

Sales & Book Value

Annual Sales
$17.89 billion
Cash Flow
$7.60 per share
Book Value
$16.94 per share

Miscellaneous

Outstanding Shares
1,212,580,000
Free Float
1,208,701,000
Market Cap
$11.70 billion
Optionable
Not Optionable
Beta
1.16

Key Executives

  • Mr. Robert J. CouryMr. Robert J. Coury (Age 61)
    Exec. Chairman
    Comp: $7.75M
  • Mr. Michael GoettlerMr. Michael Goettler (Age 54)
    CEO & Exec. Director
    Comp: $5.57M
  • Mr. Rajiv Malik (Age 61)
    Pres & Exec. Director
    Comp: $4.42M
  • Mr. Sanjeev Narula (Age 61)
    Chief Financial Officer
    Comp: $2.85M
  • Mr. Anthony Mauro (Age 49)
    Pres of Developed Markets
    Comp: $2.85M
  • Mr. Sanjeev Kumar Sethi (Age 55)
    Chief Operating Officer
  • Mr. Paul B. Campbell (Age 55)
    Chief Accounting Officer, Sr. VP & Corp. Controller
  • Mr. Ramkumar V. Rayapureddy
    Chief Information Officer
  • Ms. Melissa Trombetta
    Head of Global Investor Relations
  • Mr. Brian S. Roman (Age 52)
    Global Gen. Counsel













VTRS Stock - Frequently Asked Questions

Should I buy or sell Viatris stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Viatris in the last twelve months. There are currently 2 sell ratings and 3 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" VTRS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in VTRS, but not buy additional shares or sell existing shares.
View VTRS analyst ratings
or view top-rated stocks.

What is Viatris' stock price forecast for 2022?

5 equities research analysts have issued 1 year target prices for Viatris' shares. Their VTRS share price forecasts range from $9.00 to $19.00. On average, they predict the company's share price to reach $12.40 in the next year. This suggests a possible upside of 27.6% from the stock's current price.
View analysts price targets for VTRS
or view top-rated stocks among Wall Street analysts.

How have VTRS shares performed in 2022?

Viatris' stock was trading at $13.53 at the start of the year. Since then, VTRS shares have decreased by 28.2% and is now trading at $9.72.
View the best growth stocks for 2022 here
.

When is Viatris' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our VTRS earnings forecast
.

How were Viatris' earnings last quarter?

Viatris Inc. (NASDAQ:VTRS) issued its quarterly earnings results on Monday, August, 8th. The company reported $0.26 earnings per share for the quarter, missing the consensus estimate of $0.83 by $0.57. The firm had revenue of $4.11 billion for the quarter, compared to analyst estimates of $4.18 billion. Viatris had a trailing twelve-month return on equity of 21.30% and a net margin of 4.43%. The firm's revenue for the quarter was down 10.0% on a year-over-year basis. During the same period last year, the firm posted $0.98 EPS.
Read the conference call transcript
.

How often does Viatris pay dividends? What is the dividend yield for Viatris?

Viatris announced a quarterly dividend on Monday, August 8th. Shareholders of record on Wednesday, August 24th will be given a dividend of $0.12 per share on Friday, September 16th. This represents a $0.48 dividend on an annualized basis and a dividend yield of 4.94%. The ex-dividend date is Tuesday, August 23rd.
Read our dividend analysis for VTRS
.

Is Viatris a good dividend stock?

Viatris (NASDAQ:VTRS) pays an annual dividend of $0.48 per share and currently has a dividend yield of 5.10%. VTRS has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The dividend payout ratio is 76.19%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, VTRS will have a dividend payout ratio of 14.63% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for VTRS.

How will Viatris' stock buyback program work?

Viatris announced that its Board of Directors has authorized a stock buyback plan on Monday, February 28th 2022, which permits the company to buyback $1,000,000,000.00 in shares, according to EventVestor. This buyback authorization permits the company to reacquire up to 7.5% of its stock through open market purchases. Stock buyback plans are generally a sign that the company's board of directors believes its shares are undervalued.

What guidance has Viatris issued on next quarter's earnings?

Viatris updated its FY 2022 earnings guidance on Tuesday, September, 6th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $16.20 billion-$16.70 billion, compared to the consensus revenue estimate of $17.04 billion.

What is Michael Goettler's approval rating as Viatris' CEO?

8 employees have rated Viatris Chief Executive Officer Michael Goettler on Glassdoor.com. Michael Goettler has an approval rating of 85% among the company's employees.

What is Viatris' stock symbol?

Viatris trades on the NASDAQ under the ticker symbol "VTRS."

Who are Viatris' major shareholders?

Viatris' stock is owned by a number of institutional and retail investors. Top institutional shareholders include State Street Corp (4.79%), Laurion Capital Management LP (1.52%), Northern Trust Corp (1.02%), AQR Capital Management LLC (0.83%), Legal & General Group Plc (0.72%) and Goldman Sachs Group Inc. (0.62%). Insiders that own company stock include Der Meer Mohr Pauline Van, James M Kilts, Menassie Taddese, Michael Goettler, Robert J Coury and W Don Cornwell.
View institutional ownership trends
.

How do I buy shares of Viatris?

Shares of VTRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Viatris' stock price today?

One share of VTRS stock can currently be purchased for approximately $9.72.

How much money does Viatris make?

Viatris (NASDAQ:VTRS) has a market capitalization of $11.79 billion and generates $17.89 billion in revenue each year. The company earns $-1,269,100,000.00 in net income (profit) each year or $0.63 on an earnings per share basis.

How many employees does Viatris have?

The company employs 37,000 workers across the globe.

How can I contact Viatris?

Viatris' mailing address is 1000 MYLAN BOULEVARD, CANONSBURG PA, 15317. The official website for the company is www.viatris.com. The company can be reached via phone at (724) 514-1800, via email at investorrelations@viatris.com, or via fax at 724-514-1870.

This page (NASDAQ:VTRS) was last updated on 9/8/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.